Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by HollywoodHusson Feb 28, 2020 11:47am

102 Views

Post# 30747284

Salzsman shares

I haven't seen any serious or abmornal volume on the stock that would indicate that they have sold their shares or unloaded them by any means. Are they dumping them all at once or incrementally because I thought today was the last day for them to do so but haven't seen anything that would indicate that they have? Anyone have any insight on what they have done thus far or what the game plan is?

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute